I have a MSL panel presentation interview tomorrow on this article Tozorakimab to Prevent COPD Exacerbations F.C. Sciurba,1 H. Watz,2-4 A. Bourdin,5 W. Janssens,6 F.J. Martinez,7 J. Zheng,8 M. van den Berge,9 M. Bonini,10,11 M.L.K. Han,12 D. Singh,13,14 G.J. Criner,15 C.E. Brightling,16 A. Papi,17 S.P. Bhatt,18 M. Jenkins,19 M. Mikosz,20 P. Chołbiński,20 M. Ziemiecka,20 M. Löfdahl,21 D. Arya,22 M. Yadavalli,23 B.H. Brodek,24 M. Fagerås,25 S. Bardsley,26 N. Martin,16,26 R. Patel,27 and I. Psallidas,28 for the OBERON and TITANIA Trial Investigators*
I have a MSL panel presentation interview tomorrow on this article Tozorakimab to Prevent COPD Exacerbations F.C. Sciurba,1 H. Watz,2-4 A. Bourdin,5 W. Janssens,6 F.J. Martinez,7 J. Zheng,8 M. van den Berge,9 M. Bonini,10,11 M.L.K. Han,12 D. Singh,13,14 G.J. Criner,15 C.E. Brightling,16 A. Papi,17 S.P. Bhatt,18 M. Jenkins,19 M. Mikosz,20 P. Chołbiński,20 M. Ziemiecka,20 M. Löfdahl,21 D. Arya,22 M. Yadavalli,23 B.H. Brodek,24 M. Fagerås,25 S. Bardsley,26 N. Martin,16,26 R. Patel,27 and I. Psallidas,28 for the OBERON and TITANIA Trial Investigators*
Created using ChatSlide
This overview addresses the clinical need for effective COPD management, focusing on Tozorakimab's role in targeting IL-33-driven inflammation. It evaluates evidence on efficacy and safety, comparing exacerbation rates and interpreting lung function results. The MSL interview emphasizes translating findings into practice, considering patient selection and existing evidence gaps, with a key takeaway on assessing treatment value beyond mere statistical significance.